Eiger BioPharmaceuticals (STU:72C) GF Value Rank: 2 (As of Aug. 01, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:72C Eiger BioPharmaceuticals Inc STU:72C
10 GF Score
Price €6.18
View Full Analysis

What is Eiger BioPharmaceuticals GF Value Rank?

Eiger BioPharmaceuticals STU:72C 10 GF Value Rank is 2 as of Aug. 01, 2026, which is at its 10-year median of 2.00. GuruFocus rates STU:72C with a GF Score™ of 10/100.

Eiger BioPharmaceuticals has the GF Value Rank of 2.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Eiger BioPharmaceuticals GF Value Rank Related Terms

STU:72C vs EDSA, SIGY, EVLO: GF Value Rank Comparison

For the Biotechnology subindustry, Eiger BioPharmaceuticals's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eiger BioPharmaceuticals GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eiger BioPharmaceuticals's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Eiger BioPharmaceuticals's GF Value Rank falls into.


STU:72C
10GF Score
Eiger BioPharmaceuticals Inc STU:72C
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 2 mean?
Eiger BioPharmaceuticals (STU:72C) has a GF Value Rank of 2 as of Aug. 01, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Eiger BioPharmaceuticals and its competitors. This is near median its historical median of 2.00. Over the past decade, Eiger BioPharmaceuticals' GF Value Rank has ranged from 2.00 to 2.00.
Is Eiger BioPharmaceuticals' GF Value Rank too high?
Eiger BioPharmaceuticals' current GF Value Rank of 2 is near median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 2.00. Overall, Eiger BioPharmaceuticals has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Eiger BioPharmaceuticals' GF Value Rank compare to EDSA and SIGY?
Eiger BioPharmaceuticals' GF Value Rank of 2 can be compared against companies in the Biotechnology industry. Historically, Eiger BioPharmaceuticals' own GF Value Rank has ranged from 2.00 to 2.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Eiger BioPharmaceuticals and its competitors. Eiger BioPharmaceuticals's current GF Value Rank is 2, which is near median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiger BioPharmaceuticals stock overvalued right now?
Eiger BioPharmaceuticals (STU:72C) has a current GF Value Rank of 2. The current GF Value Rank is 2, which is near median its 10-year median of 2.00. Eiger BioPharmaceuticals' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Eiger BioPharmaceuticals (STU:72C), the current GF Value Rank is 2 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eiger BioPharmaceuticals Business Description

Address 2155 Park Boulevard, Palo Alto, CA, USA, 94306
Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
10GF Score

Get the complete analysis for STU:72C

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.18
Price